Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. - Wikidata - awgldk - TriplyDB

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

http://www.wikidata.org/entity/Q33719741

about

Ligand-directed functional selectivity at the mu opioid receptor revealed by label-free integrative pharmacology on-target Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection Lead optimization studies of cinnamic amide EP2 antagonists Prostanoid receptor EP2 as a therapeutic target Development of second generation EP2 antagonists with high selectivity Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticus Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.PROBING CANCER SIGNALING WITH RESONANT WAVEGUIDE GRATING BIOSENSORS Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease.Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus Candidate drug targets for prevention or modification of epilepsy EP2 Receptor Signaling Regulates Microglia Death.Putative role of prostaglandin receptor in intracerebral hemorrhage.Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors.Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.EP2 receptor signaling pathways regulate classical activation of microglia.Discovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.Molecular cascades that mediate the influence of inflammation on epilepsy.The role of inflammation in epileptogenesis.Prenatal exposure to common environmental factors affects brain lipids and increases risk of developing autism spectrum disorders.Cyclooxygenase-2 in glioblastoma multiforme.Cyclooxygenase-2 contributes to oxidopamine-mediated neuronal inflammation and injury via the prostaglandin E2 receptor EP2 subtype.StEPing "EP2" to Prevent Status Epilepticus-Induced Mortality and Inflammation.Differential expression of E-type prostanoid receptors 2 and 4 in microglia stimulated with lipopolysaccharide.An EP2 Agonist Facilitates NMDA-Induced Outward Currents and Inhibits Dendritic Beading through Activation of BK Channels in Mouse Cortical Neurons.Hippocampal neuronal cyclooxygenase-2 downstream signaling imbalance in a rat model of chronic aluminium gluconate administration.Internal Structure and Preferential Protein Binding of Colloidal Aggregates.Activation of EP2 receptor suppresses poly(I: C) and LPS-mediated inflammation in primary microglia and organotypic hippocampal slice cultures: Contributing role for MAPKs.Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells.Mesenchymal Stem Cells Shape Microglia Effector Functions Through the Release of CX3CL1 Human Wharton's jelly mesenchymal stem cells protect axotomized rat retinal ganglion cells via secretion of anti-inflammatory and neurotrophic factors Label-Free Biosensors for Cell Biology

P2860

Q28477403-C50CE643-8BE2-4F6A-A080-F6438913714D Q33651797-1E190A76-9FAE-4562-81D3-8101304A5051 Q33654575-AE10E648-31FF-40DE-AC3E-ED8DB39BE1D6 Q33711678-D09E672E-D8E2-499C-9B31-64E9455A132F Q33939410-16C7FC8E-96FE-438E-B50C-5B5E82CF2264 Q34018851-A6A81B54-5744-48F9-B1D7-6446A3489E11 Q34036388-DCF3F22D-7EB3-4D8E-90D8-D59ECDC721E4 Q34155940-7F435021-E532-4586-97F6-8CAB1052C2AA Q34343837-0AC81CD8-A260-48CC-9192-AC8832A1C558 Q34551101-861F869A-9426-4115-918B-911379E29ED0 Q35534894-761F20B3-3ECD-49BF-ACB4-662F5F1C6033 Q35594944-95A5993B-CED2-4248-83A3-DBD1138CE407 Q35745955-5BC197F9-460A-4F91-94BF-452462D8223C Q36337569-2203040A-381B-4183-9820-14DB207C5F77 Q36497805-32E715BF-2E79-4BE8-B263-7EF498790058 Q36573214-9A43B847-3423-4483-80CD-C7A1FCC46142 Q36653830-05A75156-175C-4B12-9523-E5FEF56608D2 Q36725062-59EB8A3B-E570-4ED3-8E82-EDB7BE7EAEAB Q37063800-88507B35-9802-484E-8A88-93B3A4C77BE5 Q37350938-3E10403E-4D85-48B0-A3E1-F61906ECF71B Q37872030-56FD3449-996B-49D4-B0CD-9018B012E19F Q38004250-3472FE85-730D-4E9F-8771-F7ED373A5BF9 Q38555255-D329A3BD-A44E-4E1C-BA4E-7C26ABF9DDEB Q38969912-4574087F-5470-4DB5-8407-E39C209F4175 Q41533962-69B8F9D3-F320-42E9-AB95-C0892E701CB9 Q41893733-F3022010-71A7-443D-93BB-32E6A36289C2 Q42330737-FD1A42FC-1421-4F2F-A1A1-C769F99453BA Q42745603-8FAE3B00-8C4B-4F0F-9E63-E57514C317A4 Q43157877-CB1CB0CA-AE90-48B6-A2B6-7E244ED4E1E3 Q45952056-0E2A63B8-7AED-42A1-9D08-BFB3A9646D67 Q47309400-215E5BC3-2BCA-4BC9-891E-678FDFDF4DB9 Q51513968-CF4239B8-6A8B-4BD7-9F67-1511F11B0998 Q57658201-F521687A-B0B1-46CB-9D01-8E3AB1304E59 Q58618229-A2D5F8F1-A464-43F8-8877-F98591EC28AA Q58687097-C8B9F02A-867D-474C-BAD1-343C1FA2413D

P2860

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

http://www.wikidata.org/entity/Q33719741

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@ast

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@en

type

label

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@ast

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@en

prefLabel

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@ast

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

@en

P1433

Q33719741-416949BF-222A-4A1F-89DF-472C18B2B363

P1476

Q33719741-261E9A20-77F2-42BC-977D-428D96588966

P2093

Q33719741-0B279055-0FC3-486F-91F7-D95CCC134E30

Q33719741-160FE691-6233-4855-A6F5-A3EA027E6A95

Q33719741-327D2638-CF3F-4CDB-AC25-C8C2511E8A7D

Q33719741-3E690F86-62CF-4D4C-AB14-52D7A8C1D9BC

Q33719741-67B501E3-8594-4B94-B12C-D40262CBC2E3

Q33719741-729FD0EC-C934-4783-A055-20D02A8D8325

Q33719741-7EFFA333-0EA0-4663-BE9E-BE6FC0426BF0

Q33719741-99431CB0-82D1-41FD-8D48-1FB006BCE67D

Q33719741-BD7CA4BF-0155-420C-BDC0-63CA135C1DA6

Q33719741-C802CCF8-0439-4FA7-821C-AA6682DA238F

P2860

Q33719741-0356FEE2-C6C9-4571-BD8B-CE333FA03A3C

Q33719741-0C29EC1F-F043-4B20-8294-97556F3478C1

Q33719741-1739C3F0-61FB-45A4-97D0-9E12101ABC65

Q33719741-1F32529F-EC1E-42A8-B82C-FBA6F790D977

Q33719741-20F05D64-CE23-453C-8A70-25CB6D3E86F8

Q33719741-27710949-78D9-4BCA-85C9-17D174B1A3A8

Q33719741-34E766D8-D532-46D0-B7A7-41147E70E624

Q33719741-4E0B135D-F49B-4E34-B49A-7C0DB9C411E2

Q33719741-5A808D69-6E83-48DC-A262-F203E41BE17A

Q33719741-5CCDBDCC-0CC7-481D-B375-CD74480FE839

P304

Q33719741-F28E76FD-F07C-4472-AFCA-655D0BA087F5

P31

Q33719741-2A5F7897-C077-44B1-B4F9-1D904F73B4A1

P356

Q33719741-74D00E81-1561-4683-85A3-CD4ED051B30D

P433

Q33719741-F25D189B-89BB-4F1A-A2E1-B05B94AF9F13

P478

Q33719741-AAD34C50-E4EE-4D83-B55A-81945884D788

P50

Q33719741-1CBBD155-12D9-4B13-AF93-F1711693E8F1

P577

Q33719741-EA9B512B-CDA4-4FE4-9145-879D6586D3FB

P5875

Q33719741-162549F1-0B37-40B4-9831-35948C7D92B2

P698

Q33719741-75056296-652A-4BC3-A7C4-C788A1EF4E6A

P932

Q33719741-E2E28144-0122-4F21-BD7A-6440F133B7B2

P356

PNAS.0909310107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor

@en

P2093

Aiming Sun

http://www.w3.org/2001/XMLSchema#string

Asheebo Rojas

http://www.w3.org/2001/XMLSchema#string

Geidy Serrano

http://www.w3.org/2001/XMLSchema#string

Iestyn Lewis

http://www.w3.org/2001/XMLSchema#string

Lian Li

http://www.w3.org/2001/XMLSchema#string

Min Qui

http://www.w3.org/2001/XMLSchema#string

Pahk Thepchatri

http://www.w3.org/2001/XMLSchema#string

Ray Dingledine

http://www.w3.org/2001/XMLSchema#string

Renee Shaw

http://www.w3.org/2001/XMLSchema#string

Serdar Kurtkaya

http://www.w3.org/2001/XMLSchema#string

P2860

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

LeadScope: data visualization for large volumes of chemical and biological screening data.

Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia.

Allosteric binding sites on cell-surface receptors: novel targets for drug discovery.

Prostanoid receptors: subtypes and signaling.

Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist.

Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.

NMDA receptor pathways as drug targets.

An EP2 receptor-selective prostaglandin E2 agonist induces bone healing.

Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor.

P304

2307-2312

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0909310107

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Jianxiong Jiang

P577

2010-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41040279

http://www.w3.org/2001/XMLSchema#string

P698

20080612

http://www.w3.org/2001/XMLSchema#string

P932

2836658

http://www.w3.org/2001/XMLSchema#string